IN2012DN02139A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02139A
IN2012DN02139A IN2139DEN2012A IN2012DN02139A IN 2012DN02139 A IN2012DN02139 A IN 2012DN02139A IN 2139DEN2012 A IN2139DEN2012 A IN 2139DEN2012A IN 2012DN02139 A IN2012DN02139 A IN 2012DN02139A
Authority
IN
India
Prior art keywords
compounds
medicament
substituents
processes
formula
Prior art date
Application number
Inventor
Bei Chen
Robin Alec Fairhurst
Andreas Floersheimer
Pascal Furet
Vito Guagnano
Songchun Jiang
Wenshuo Lu
Thomas H Marsilje
Clive Mccarthy
Pierre-Yves Michellys
Frederic Stauffer
Stefan Stutz
Andrea Vaupel
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of IN2012DN02139A publication Critical patent/IN2012DN02139A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to compounds of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.
IN2139DEN2012 2009-09-10 2010-09-10 IN2012DN02139A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24118209P 2009-09-10 2009-09-10
PCT/EP2010/063334 WO2011029915A1 (en) 2009-09-10 2010-09-10 Ether derivatives of bicyclic heteroaryls

Publications (1)

Publication Number Publication Date
IN2012DN02139A true IN2012DN02139A (en) 2015-08-07

Family

ID=43511862

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2139DEN2012 IN2012DN02139A (en) 2009-09-10 2010-09-10

Country Status (12)

Country Link
US (1) US20120165310A1 (en)
EP (1) EP2475668A1 (en)
JP (1) JP2013504543A (en)
KR (1) KR20120093867A (en)
CN (1) CN102596963A (en)
AU (1) AU2010294209A1 (en)
BR (1) BR112012005400A2 (en)
CA (1) CA2773661A1 (en)
EA (1) EA201200471A1 (en)
IN (1) IN2012DN02139A (en)
MX (1) MX2012002997A (en)
WO (1) WO2011029915A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9273056B2 (en) * 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
TW201348231A (en) 2012-02-29 2013-12-01 Amgen Inc Heterobicyclic compounds
CA2873878A1 (en) 2012-05-22 2013-11-28 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
AU2013344049B2 (en) 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
CN106459063A (en) 2014-04-11 2017-02-22 北卡罗来纳-查佩尔山大学 MerTK-specific pyrimidine compounds
CA3006966A1 (en) * 2015-12-02 2017-06-08 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN106008527B (en) * 2016-06-29 2018-05-15 四川大学华西医院 Pyrazolo [3,4-d] pyrimidine derivatives
CN107098909B (en) * 2017-05-19 2019-02-22 四川大学华西医院 The aminopyridine derivative and antitumor application thereof of alcoxyl end group widow PEG modification
WO2021155004A1 (en) * 2020-01-30 2021-08-05 The Regents Of The University Of California Strad-binding agents and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
RO119721B1 (en) 1992-10-28 2005-02-28 Genentech Inc. Antagonists of vascular endotelial cell growth factor
NZ293249A (en) 1994-09-29 1999-04-29 Novartis Ag 4-amino-5,7-diaryl-pyrrolo[2,3-d]pyrimidines and their use
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6140332A (en) 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
GB9517060D0 (en) 1995-08-17 1995-10-25 Ciba Geigy Ag Acylated oligopeptide derivatives
GB9516842D0 (en) 1995-08-17 1995-10-18 Ciba Geigy Ag Various acylated oligopeptides
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimides and their use.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
WO1997032879A1 (en) 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES
PL190489B1 (en) 1996-04-12 2005-12-30 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ATE308527T1 (en) 1996-06-24 2005-11-15 Pfizer PHENYLAMINO-SUBSTITUTED TRIICYCLIC DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
JP4731016B2 (en) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド Vascular endothelial growth factor antagonists and their uses
ES2265929T3 (en) 1999-03-30 2007-03-01 Novartis Ag FTALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES.
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6706731B2 (en) 2000-02-09 2004-03-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2002092559A1 (en) 2001-05-11 2002-11-21 Wako Pure Chemical Industries, Ltd. Fluorinated triphenylsulfonium salts
AR035885A1 (en) * 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN1898240B (en) * 2003-10-15 2011-08-03 Osi制药公司 Imidazopyrazine tyrosine kinase inhibitors
CA2561950C (en) 2004-04-02 2010-04-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
CA2589171A1 (en) 2004-11-29 2006-06-01 Pharmacia & Upjohn Company Llc Thiazepine oxazolidinones as antibacterial agents
TW200730529A (en) 2005-12-07 2007-08-16 Osi Pharm Inc Process to prepare substituted imidazopyrazine compounds
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
UY31545A1 (en) 2007-12-20 2009-08-03 NEW DERIVATIVES OF 2-CARBOXAMIDE CIANOAMINOUREA, ITS SALTS AND PHARMACEUTICALLY ACCEPTABLE PROFARMS, PREPARATION PROCESSES AND APPLICATIONS

Also Published As

Publication number Publication date
CA2773661A1 (en) 2011-03-17
EP2475668A1 (en) 2012-07-18
AU2010294209A1 (en) 2012-03-29
BR112012005400A2 (en) 2016-04-05
JP2013504543A (en) 2013-02-07
US20120165310A1 (en) 2012-06-28
KR20120093867A (en) 2012-08-23
EA201200471A1 (en) 2012-10-30
CN102596963A (en) 2012-07-18
WO2011029915A1 (en) 2011-03-17
MX2012002997A (en) 2012-08-01

Similar Documents

Publication Publication Date Title
IN2012DN02139A (en)
NZ608116A (en) Triazine-oxadiazoles
PH12015501385A1 (en) Autotaxin inhibitors
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
GB201118656D0 (en) New compounds
MX2010007587A (en) Compounds comprising a cyclobutoxy group.
MY165087A (en) Neprilysin inhibitors
MY173448A (en) Phenyl and benzodioxinly substituted indazoles derivatives
MX2011008864A (en) Sulfonylated tetrahydroazolopyrazines and their use as medicinal products.
MX343706B (en) Novel heterocyclic derivatives.
MX2013010898A (en) Novel pyrimidine derivatives.
MX2012013274A (en) Novel pyrimidine derivatives.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
MY187718A (en) Pharmaceutical formulations
IN2012DN03182A (en)
WO2013040227A3 (en) Therapeutic compounds
MX355072B (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX360330B (en) Administration regime for nitrocatechols.
IN2012DN01292A (en)
MY152018A (en) Indole derivatives as anticancer agents
MX2013003202A (en) Oxadiazole inhibitors of leukotriene production.
WO2010081731A3 (en) Derivatives of syringolin a
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.